Drugs A-Z Is my price fair? Price changes Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Generic drug

Hydrocodone price, strengths & recalls

Generic of Hysingla

Pharmacies pay $238.16 for 30 capsules of Hydrocodone 15 mg (12 hr) extended-release capsule this week. 1 recall is ongoing. Its official label last changed on October 2, 2026.

1 open recallGeneric
Pharmacies pay$238.16for 30 capsules of 15 mg (12 hr) extended-release capsule-0.1% in 4 weeks
Fair cash price
$284.38
Strengths
1
Makers
1
Updated
Nov 11

Hydrocodone price by strength

What pharmacies pay for each strength and form this week (Nov 11, 2026), for the usual package. Choose one for its fair price, 52-week chart and makers.

Strength and formPer unitPharmacies pay4 weeks52 weeks
15 mg (12 hr) extended-release capsule$7.94$238.16 / 30 capsules-0.1%+33.8%
20 mg (12 hr) extended-release capsuleNot priced this week
30 mg (12 hr) extended-release capsuleNot priced this week
20 mg extended-release tabletNot priced this week

Brand names of hydrocodone

A brand and its generic share the active ingredient; the generic is almost always far cheaper.

Supply status: shortages & recalls

No shortage reportedChecked Nov 16, 2026
1 ongoing recall16 recalls on record, latest Nov 25, 2020

Recalls

Class IOngoingNov 28, 2012HYDROCODONE BITARTRATE and ACETAMINOPHEN TABLETSSuperpotent (Multiple Ingredient) Drug: Confirmed customer complaints of oversized tablets resulting in superpotent assays of both the hydrocodone and acetaminophen...Vintage Pharmaceuticals LLC DBA Qualitest Pharmaceuticals · D-057-2013Class IITerminatedNov 25, 2020Hydrocodone Bitartrate and Acetaminophen TabletsPresence of Foreign Tablet/Capsule: One bottle of Hydrocodone Bitartrate and Acetaminophen Tablets USP 10mg/325 mg contains one Losartan Potassium Tablets, USP 100 mg.Ascent Pharmaceuticals, Inc. · D-0097-2021Class IITerminatedJun 19, 2019Hydrocodone Bitartrate and Homatropine Methylbromide Oral SolutioncGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).Torrent Pharma Inc · D-1383-2019Class IITerminatedJun 19, 2019Hydrocodone Bitartrate and Homatropine Methylbromide Oral SolutioncGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).Torrent Pharma Inc · D-1384-2019Class IIITerminatedFeb 21, 2018NORCO (Hydrocodone Bitartrate and Acetaminophen) TabletsLabeling: Not Elsewhere Classified: does not have the required "CII" controlled drug classification indication on the primary label.Allergan · D-0413-2018Class IIITerminatedSep 20, 2017Hydrocodone Bitartrate and Acetaminophen Oral Solution 7.5 mg/325 mg per 15 mLLabeling: Not Elsewhere Classified; product is incorrectly labeled as Class III controlled substance instead of Class II controlled substanceVistaPharm, Inc. · D-1139-2017

Showing the 6 most relevant of 16 - all recalls.

A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.

What did you pay for hydrocodone? Help the next person.

Every price shared helps the next person know what's fair - and shows which pharmacies charge the least. Anonymous, 30 seconds.

How were you treated? optional

Free, anonymous, no sign-up. Please don't include personal or health details. Community rules.

Official label & what changed

Last changedOctober 2, 2026
Version10 of 7
EffectiveJan 31, 2026
Read the label

These highlights do not include all the information needed to use HYDROCODONE BITARTRATE EXTENDED-RELEASE CAPSULES safely and effectively. See full prescribing information for HYDROCODONE BITARTRATE EXTENDED-RELEASE CAPSULES. HYDROCODONE BITARTRATE extended-release capsules, for oral use, CII Initial U.S. Approval: 1943

This drug has a boxed warning

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROCODONE BITARTRATE EXTENDED-RELEASE CAPSULES

Addiction, Abuse, and Misuse

Because the use of hydrocodone bitartrate extended-release capsules exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death, assess each patient's risk prior to prescribing and reassess all patients regularly for the development of these behaviors and conditions[see Warnings and Precautions (5.1)].

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of hydrocodone bitartrate extended-release capsules, especially during initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of hydrocodone bitartrate extended-release capsules are essential. Instruct patients to swallow hydrocodone bitartrate extended-release capsules whole; crushing, chewing, or dissolving hydrocodone bitartrate extended-release capsules can cause rapid release and absorption of a potentially fatal dose of hydrocodone[see Warnings and Precautions (5.2)].

Accidental Ingestion

Accidental ingestion of even one dose of hydrocodone bitartrate extended-release capsules, especially by children, can result in a fatal overdose of hydrocodone[see Warnings and Precautions (5.2)].

Interaction with Alcohol

Instruct patients not to consume alcoholic beverages or use prescription or non-prescription products that contain alcohol while taking hydrocodone bitartrate extended-release capsules. The co-ingestion of alcohol with hydrocodone bitartrate extended-release capsules may result in increased plasma levels and a potentially fatal overdose of hydrocodone[see Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)].

Risks From Concomitant Use with Benzodiazepines or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of hydrocodone bitartrate extended-release capsules and benzodiazepines or other CNS depressants for use in patients for whom alternative treatment options are inadequate[see Warnings and Precautions (5.3), Drug Interactions (7)].

Neonatal Opioid Withdrawal Syndrome (NOWS)

Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery[see Warnings and Precautions (5.4)].

Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS)

Healthcare providers are strongly encouraged to complete a REMS-compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription[see Warnings and Precautions (5.5)].

Cytochrome P450 3A4 Interaction

The concomitant use of hydrocodone bitartrate extended-release capsules with all cytochrome P450 3A4 inhibitors may result in an increase in hydrocodone plasma concentrations, which could increase or prolong adverse drug effects and may cause potentially fatal respiratory depression. In addition, discontinuation of a concomitantly used cytochrome P450 3A4 inducer may result in an increase in hydrocodone plasma concentration. Regularly evaluate patients receiving hydrocodone bitartrate extended-release capsules and any CYP3A4 inhibitor or inducer[see Warnings and Precautions (5.6), Drug Interactions (7), and Clinical Pharmacology (12.3)].

WARNING: SERIOUS AND LIFE-THREATENING RISKS FROM USE OF HYDROCODONE BITARTRATE EXTENDED-RELEASE CAPSULES

See full prescribing information for complete boxed warning.

Hydrocodone bitartrate extended-release capsules exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Assess patient's risk before prescribing and reassess regularly for these behaviors and conditions. (5.1)

Serious, life-threatening, or fatal respiratory depression may occur, especially upon initiation or following a dosage increase. To reduce the risk of respiratory depression, proper dosing and titration of hydrocodone bitartrate extended-release capsules are essential. Instruct patients to swallow hydrocodone bitartrate extended-release capsules whole to avoid exposure to a potentially fatal dose of hydrocodone. (5.2)

Accidental ingestion of hydrocodone bitartrate extended-release capsules, especially in children, can result in a fatal overdose of hydrocodone. (5.2)

Instruct patients not to consume alcohol or any products containing alcohol while taking hydrocodone bitartrate extended-release capsules because co-ingestion can result in fatal plasma hydrocodone levels. (5.3)

Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate. (5.3, 7)

Advise pregnant women using opioids for an extended period of time of the risk of Neonatal Opioid Withdrawal Syndrome, which may be life-threatening if not recognized and treated. Ensure that management by neonatology experts will be available at delivery. (5.4)

Healthcare providers are strongly encouraged to complete a REMS compliant education program and to counsel patients and caregivers on serious risks, safe use, and the importance of reading the Medication Guide with each prescription. (5.5)

Concomitant use with CYP3A4 inhibitors (or discontinuation of CYP3A4 inducers) can result in a fatal overdose of hydrocodone. (5.6, 7, 12.3)

Recent major changes (as listed on the label)

Boxed Warning | 12/2025 |

Indications and Usage (1) | 12/2025 |

Dosage and Administration (2.2, 2.3, 2.6) | 12/2025 |

Warnings and Precautions (5.1, 5.2, 5.3, 5.12, 5.14) | 12/2025 |

We check this label every day. When it changes, the sections that changed appear here, old text beside new.

We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.

Approval, patents & generics

Generic makers
2 approved generic applications on the market
Last patent listed
December 21, 2031

Hydrocodone questions

How much does hydrocodone cost without insurance?

Pharmacies pay about $238.16 for 30 capsules of hydrocodone 15 mg (12 hr) extended-release capsule ($7.94 per capsule). A fair cash price - that cost plus a 15% margin and a typical dispensing fee - is about $284.38. If you're quoted much more, check your quote and ask for the pharmacy's cash price.

What is the brand name of hydrocodone?

Hydrocodone is sold as Hysingla. The generic has the same active ingredient and usually costs far less.

Is hydrocodone in shortage?

No shortage is reported for hydrocodone right now. We check the national shortage list every day.

Has hydrocodone been recalled?

16 recalls on record, 1 ongoing. Recalls name specific lots - check yours.

When did the hydrocodone label last change?

The official label was last updated on October 2, 2026 (version 10). See what changed.

Talk about hydrocodone

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.